@kellykilleenmd's peptide therapy claims need scrutiny

What did @kellykilleenmd actually say?

Dr. Kelly Killeen called out a TikTok video showing someone reconstituting peptides at home, arguing the technique was wrong and the sourcing was legally questionable. Her core complaint: you don't need to remove the stopper from a vial to draw medication, and repeatedly puncturing a rubber stopper with a fine needle can cause rubber particulate contamination. She also flagged that the peptide source, apparently a nurse in Rhode Island selling across state lines, raises serious legal red flags.

This wasn't a clinical lecture. It was a physician watching a bad tutorial and saying, plainly, "what are we doing?" That framing matters. She's not disputing the existence of peptide therapy. She's objecting to unverified substances, improper technique, and unlicensed distribution dressed up as helpful content.

Does the science back this up?

On the coring and particulate contamination point, yes, the evidence supports her concern. Studies on rubber stopper integrity show that repeated needle penetration, especially with smaller-gauge needles, can produce rubber particles that enter the solution. This is well-documented in pharmaceutical compounding literature.

A 2014 study by Sacha et al. published in the PDA Journal of Pharmaceutical Science and Technology confirmed that repeated puncture of elastomeric closures generates particulate matter, with frequency and needle gauge both affecting contamination rates. Thinner needles, like the 32-gauge she mentions, can actually score and fragment the stopper more unpredictably than larger ones because they create smaller, less clean punctures.

The standard practice in clinical settings is to use an alcohol-wiped septum and a single clean puncture, not repeated insertions through the same spot with a needle that's been used multiple times. Her point about decapping being unnecessary unless you're removing the stopper entirely is also consistent with standard sterile compounding protocols.

What did they get wrong (or right)?

She got the core safety point right. Repeated stopper puncture with fine needles is a real contamination risk, not a theoretical one. The pharmacy compounding literature backs her up here.

She also correctly identified that distribution of compounded peptides across state lines by a non-licensed distributor is legally problematic. The FDA's jurisdiction over compounded drugs, combined with state pharmacy board regulations, means that a nurse in Rhode Island mailing peptides to customers in other states is operating in territory that could constitute unlicensed drug distribution.

Where her video is less precise: she doesn't distinguish between which specific peptides are FDA-approved, which are on the 503B outsourcing facility lists, and which are essentially unregulated research chemicals. "Glow peptides" is a vague category. GHK-Cu, for instance, has a different regulatory status than BPC-157. Lumping them together as "legally questionable" is directionally correct but imprecise. She also doesn't address that even when sourced from a licensed compounding pharmacy, reconstitution errors at home remain a separate safety issue.

What should you actually know?

If you are using or considering injectable peptides for cosmetic or recovery purposes, the sourcing and handling questions Dr. Killeen raises are the right ones to be asking. Here's what the regulatory landscape actually looks like right now.

• The FDA has classified several popular peptides, including BPC-157, as not eligible for compounding under federal law, meaning licensed 503A pharmacies cannot legally compound them for human use. This doesn't stop people from selling them as "research chemicals," but that designation does not make them safe or legal for injection.
• Rubber stopper coring is a documented pharmaceutical safety concern. The USP General Chapter 1 on injections and the PDA's technical reports both address particulate contamination from closures. Using a 32-gauge needle repeatedly through the same stopper is not best practice under any clinical standard.
• State lines matter. Drug distribution is regulated at both the federal and state level. A nurse cannot legally ship compounded prescription medications to patients in other states without proper licensing in each state and a valid prescriber-patient relationship.
• "You can't verify" what's in an unregulated peptide is not just a rhetorical point. Third-party testing of peptides sold online has repeatedly shown dosing inconsistencies and contamination. A 2021 analysis published in Drug Testing and Analysis by Griffiths et al. found significant discrepancies between labeled and actual peptide content in samples purchased from online vendors.

The bottom line: the concerns Dr. Killeen raises about technique and sourcing are grounded in real regulatory and safety evidence. If you're receiving peptide therapy, it should be through a licensed provider using a licensed compounding pharmacy, with proper reconstitution instructions, not from a tutorial filmed in someone's bathroom.